What You Should Know:
– COTA, Inc., an oncology real-world data and analytics company and the University of Chicago Medicine announced a research collaboration agreement to investigate racial disparities of care in multiple myeloma to better understand differences in the diagnosis, treatment patterns, and outcomes of patients with this type of cancer.
– Multiple myeloma is the second-most-common hematologic malignancy, with an estimated 34,920 new cases and 12,410 deaths expected to occur in the United States in 2021. Research has shown that the incidence rate of myeloma in Black Americans is two to three times higher than in other populations — and the death rates are higher as well. Researchers at COTA and the University of Chicago Medicine will use real-world data to examine potential disparities in clinical treatment pathways and outcomes.
– Researchers at COTA and the University of Chicago Medicine will use real-world data to examine disparities in clinical treatment pathways and outcomes specific to patients with multiple myeloma – a cancer that disproportionately affects Black Americans yet who also are sorely underrepresented in clinical trials.